Microbot Medical (MBOT) CEO to discuss FDA-cleared LIBERTY on Benzinga

Rhea-AI Filing Summary

Microbot Medical Inc. filed a current report to share that its Chief Executive Officer, Harel Gadot, will appear on Benzinga All Access at 10:45 a.m. ET on Wednesday, September 24, 2025. During the interview, he is expected to discuss the recent FDA clearance of the Company’s LIBERTY® system and how the Company has planned for its commercialization in the United States.

The Company furnished a related press release as Exhibit 99.1, and this communication is being treated as “furnished” rather than “filed” under securities laws. The filing highlights ongoing communication with the market about Microbot Medical’s efforts to redefine the peripheral endovascular space with its LIBERTY® technology.

false 0000883975 0000883975 2025-09-23 2025-09-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 23, 2025

MICROBOT MEDICAL INC.

(Exact name of registrant as specified in its charter)

Delaware		000-19871		94-3078125
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

175 Derby St., Bld. 27

Hingham, MA 02043

(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code: (781) 875-3605

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.01 par value		MBOT		NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On September 23, 2025, Microbot Medical Inc. (the “Company”) issued a press release announcing that its Chief Executive Officer, Harel Gadot, will be interviewed on Benzinga All Access at 10:45am ET on Wednesday, September 24, 2025, where he will discuss the recent FDA clearance of the Company’s LIBERTY®, and how the Company has planned for commercialization in the U.S. as it redefines the peripheral endovascular space with LIBERTY®.

The press release, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K, is incorporated herein by reference. The information in this Item 7.01 and Exhibit 99.1 is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information in this Item 7.01 or Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		Press Release
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	MICROBOT MEDICAL INC.
	By:	/s/ Harel Gadot
	Name:	Harel Gadot
	Title:	Chief Executive Officer, President and Chairman

Date: September 23, 2025

FAQ

What did Microbot Medical (MBOT) disclose in this 8-K filing?

Microbot Medical disclosed that its CEO, Harel Gadot, will be interviewed on Benzinga All Access, where he will discuss the recent FDA clearance of the Company’s LIBERTY® system and its planned commercialization in the U.S.

When will the Microbot Medical CEO appear on Benzinga All Access?

The CEO of Microbot Medical is scheduled to appear on Benzinga All Access at 10:45 a.m. ET on Wednesday, September 24, 2025.

What product is Microbot Medical’s CEO expected to discuss in the Benzinga interview?

He is expected to discuss the Company’s LIBERTY® system, including its recent FDA clearance and how Microbot Medical has planned for commercialization in the U.S.

How is the information in this Microbot Medical 8-K treated under securities laws?

The information in Item 7.01 and Exhibit 99.1 is being furnished, not filed, for purposes of Section 18 of the Securities Exchange Act of 1934, meaning it is not subject to the same liability provisions as filed information.

What exhibit is attached to this Microbot Medical (MBOT) 8-K?

The filing includes Exhibit 99.1, which is a press release relating to the CEO’s upcoming Benzinga All Access interview and the discussion of the LIBERTY® system.

Does this Microbot Medical 8-K announce financial results or major transactions?

No. The 8-K focuses on a Regulation FD disclosure about an upcoming media appearance and discussion of the FDA-cleared LIBERTY® system and its planned U.S. commercialization.